Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 08, 2026
Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 08, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617.
Journal: Radiology
Published: March 31, 2026
Obesity's Disparate Impact on COVID-19 Outcomes in Asian American Patients with Cancer.
Journal: medRxiv : the preprint server for health sciences
Published: June 04, 2025
Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort study.
Journal: Urologic oncology
Published: March 24, 2025
Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency.
Journal: European urology oncology
Published: February 14, 2025
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies.
Journal: Cancer research communications
Published: February 06, 2025
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 29, 2024
Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer.
Journal: The Journal of clinical investigation
Published: September 03, 2024
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.
Journal: European urology oncology
Published: August 19, 2024
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 29, 2024
Last Updated: 09/26/2026